Don’t miss the latest developments in business and finance.

Aurobindo Pharma receives final approval for Esomeprazole Magnesium Delayed-Release Capsules

Image
Capital Market
Last Updated : Oct 17 2017 | 12:28 PM IST

From USFDA

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg. Esomeprazole Magnesium Delayed-Release Capsules OTC, a therapeutic equivalent generic version of AstraZeneca's Nexium 24HR Capsules. The product will be launched immediately.

Nexium 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week). The approved product has an approximate annual sales in excess of US$ 300 million, according to IRI database.

This is the 127th ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 335 ANDA approvals (296 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Oct 17 2017 | 12:14 PM IST

Next Story